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Background: In 2005 Best and Quinton established the salivary secretion assay in mice for the in vivo characterization of new drugs against cystic
ﬁbrosis (CF). However, limited data are available and the predictive value of this in vivo assay for treatment effects in CF patients is not fully understood.
Methods: Therefore, we revisited the salivary secretion assay and systematically investigated the salivary secretion rates in different murine
backgrounds and sexes, as well as in different CF mouse models. Moreover, we established quantiﬁcation of salivary chloride content.
Results: We found a strain- and sex-dependency of salivary secretion rates and were able to conﬁrm the decreased β-adrenergic salivary secretion
response in CFTR knockout mice (CFTRtm1Unc) as well as in the F508del CFTR mice of different origins (CFTRtm1Kth and CFTRtm1Eur). In
heterozygous Cftr+/− and Cftr+/F508del mice, the isoprenaline-stimulated salivary secretion rate and the Cl− content were intermediate between
values measured in WT and CF mice, indicating that this assay is also able to detect CF carriership. Pilocarpine-induced abnormalities in saliva
chloride content in CF mice resembled the changes observed in the human sweat test.
Conclusions: Determination of murine salivary chloride content in combination with salivary secretion rate in CF mice may render the salivary
secretion assay as a powerful tool for validation of new CF treatments.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Salivary secretion assay; Cystic ﬁbrosis; Salivary chloride content; Human sweat test1. Introduction
Cystic fibrosis (CF) is one of the most prevalent autosomal
recessive disorders which substantially decreases the quality of
life as well as the life-expectancy [1]. CF is caused by mutations
in the gene encoding the cystic fibrosis transmembrane conduc-
tance regulator (CFTR), which is a cAMP-regulated chloride
channel. CFTR-mutations, of which the F508del CFTR-mutation
is the most prevalent, lead to inadequate CFTR-processing,
partially impaired CFTR-insertion into epithelial cell mem-
branes, decreased CFTR-functionality, and/or increased CFTR-
degradation [2]. As a result, the F508del CFTR-mutation causes a⁎ Corresponding author at: Global Drug Discovery— Common Mechanism
Research, Bayer HealthCare, Aprather Weg 18a, 42096 Wuppertal, Germany.
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http://dx.doi.org/10.1016/j.jcf.2013.05.001significant reduction of trans-epithelial chloride and bicarbonate
transport, which results in thick and sticky mucus formation,
especially in the respiratory tract [3].
Currently, most of the treatment approaches are symptomatic,
including antibiotics, glucocorticoids, DNAase, inhaled saline or
physical therapy [4]. Causal therapies for CF-patients for the
improvement of F508del CFTR processing and function are still
lacking and currently only the potentiator Ivacaftor (VX-770),
which improves CFTR gating, is approved for the treatment of the
G551D CFTR-mutation. This lack of causal therapy is rather
surprising since for many years, intense research and development
efforts were made in academia as well as in the pharmaceutical
industry, to identify new compounds that correct and potentiate
F508del-CFTR function. Therefore this lack of efficacious
treatment could raise concerns about the predictability of the
preclinical screening cascade for profiling potential new treatment
options. Currently, there is a variety of in vitro test systemsby Elsevier B.V. All rights reserved.
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membrane insertion, expression and function in transfected cells, in
reporter cell assays or in bronchial epithelia cells of CF patients
[5–7,9]. These systems allow a close look at the mode of action
and at F508del CFTR-function, but are partially limited by their in
vitro environment that does not fully mimic integration in an
organism [7]. Occasionally, these in vitro assays are combinedwith
in vivo animal experiments, mostly in CFTR knockout and
F508del CFTR transgenic mice which should – at least partly –
reflect the situation in CF patients. In the clinics, sweat-chloride
content and nasal PD measurements are used as validated
diagnostic tools, but also as early hints for efficacy of new
pharmacological treatment approaches. Recently, it was tried to
adapt this read-outs to the murine situation by measurement of
salivary secretion in the transgenic CF mouse models. Best and
Quinton developed a salivary secretion assay in CFTR deficient
mice to study CFTR-dependent saliva secretion [8], which was
later partially extended to F508del transgenic mice [9,10].
Nevertheless, there is only limited information on the effects of
potential new CF-treatment options available [9,11] and questions
are raised about the predictive value of these in vivo assays in CF
mice [12,13]. This is partly due to the lack of consistent and
systematic in vivo data in the CF mouse models, which are rather
difficult to obtain since different murine backgrounds, different
sexes and different transgenic animals are used. The transgenic
animals comprise CFTR knockout mice (CFTRtm1Unc), but also
different F508del transgenic mouse models, e.g. CFTRtm2Cam,
CFTRtm1Eur, or CFTRtm1Kth [14]. In addition, secretion rates do
only mirror one feature of the sweat test, namely sweat production.
Sweat chloride content, which will allow a more direct link to
CFTR function, and which is monitored in the CF patients, is not
measured in the murine assays so far. In order to address all
these questions we systematically analysed salivary secretion
in C57Bl/6, FVB/N, Sv/129, C3H/He mice backgrounds of
both sexes. In addition, we compared salivation rates in
CFTR knockout mice (CFTRtm1Unc) and in F508del transgenic
CFTRtm1Eur and CFTRtm1Kth mice. Finally, we used a modified
pilocarpine-induced salivary secretion assay – since pilocarpine is
used in the human sweat test – and quantified saliva chloride
content in the different aforementioned CF models. Our results
imply that salivary secretion is genetic background- and sex-
dependent. Moreover, our results in complementary CF mouse
models, especially in CFTR deficient, homozygous and heterozy-
gous CFTRtm1Eur and CFTRtm1Kth mice provide a strong link with
the chloride secretion and reabsorption abnormalities in the sweat
gland of CF patients. Finally, saliva chloride content in the different
CF mouse models is also correlated with the well-established
abnormal sweat chloride content in CF patients.
2. Methods
2.1. Mice
Six- to 12-week-old male and female C57Bl/6, FVB/N, Sv/
129 and C3H/He mice were obtained from Charles River
Laboratories (Sulzfeld, Germany). A colony of knockout
CFTRtm1Unc mice (Jackson Laboratory, USA) and two strainsof F508del mice CFTRtm1Eur (originally obtained from B.
Scholte, Department of Cell Biology, Erasmus Medical Centre
(EMC), Rotterdam, Netherlands) and CFTRtm1Kth (Jackson
Laboratory, USA) were established by mating heterozygous
animals. Male and female homozygous, heterozygous and
wild-type CF-mice at the age of 6–12 weeks were obtained
from the animal breeding facilities at Bayer Health Care
(Wuppertal, Germany) and used for this study. To avoid
intestinal blockage, the most common cause of death in CF
mice, homozygous mice were maintained on a special diet
(S0602-S710, SM AB diets Breeding, Ssniff Spezialdiäten
GmbH, Soest, Germany). In addition an osmotic laxative,
an electrolyte solution containing polyethylene glycol 3350
(Klean-Prep®; Norgine GmbH, Marburg, Germany) was admin-
istered ad libitum in the drinking water of CFTRtm1Unc mice. All
animal studies were approved by the Institutional Animal
Management and Care facility as per German law for the
protection of laboratory animals and local government and
internal regulations of the Use Committee LANUV NRW
(Landesamt für Natur, Umwelt und Verbraucherschutz).
2.2. Salivary secretion assay (SSA), saliva collection and
chloride content determination
The anaesthesia and the salivary secretion assay (SSA) were
performed as previously described [8] and modified for
quantification of saliva chloride content. Pharmacological
stimulation of saliva flow was performed in anaesthetized
mice by subcutaneous injection of cholinergic or adrenergic
agents into the left cheek. Anaesthesia was performed by
intraperitoneal injection of ketamine (5 mg/kg BW; Pfizer,
Berlin, Germany) and diazepam (0.25 mg/kg BW; Rotexmedica,
Trittau, Germany) in sterile physiological saline (5 ml/kg BW).
The cholinergic stimulation was induced by subcutaneous
injection of 50 μl of acetylcholine or pilocarpine solutions
(100 μM dissolved in isotonic NaCl). Before adrenergic
stimulation the cholinergic system was blocked by subcutaneous
injection of 50 μl of 1 mM atropine dissolved in isotonic NaCl.
Thereafter, small strips of filter paper were placed inside the
previously injected cheek for 4 min to absorb any saliva secreted
after the injection of atropine till fully blocking the cholinergic
system by atropine. For consecutive induction of adrenergic-
induced salivary secretion, a solution containing 100 μM
isoprenaline in 50 μl was injected into the left cheek containing
also 1 mM atropine in order to maintain cholinergic blockade
throughout the experiment. The saliva was collected with small
pieces (2 × 2.5 mm) ofWhatman paper (Whatman® quantitative
filter paper, ashless, Grade 40), or in the case of chloride
determination with a glass capillary tube (Sigma-Aldrich,
Deisenhofen, Germany) both inserted in the mouth. Saliva was
collected over a period of 30 min. Filter paper strips were
replaced every 10 min, and capillary tubes were replaced when
they become filled with saliva. At the end of the experiment, the
net weight of saliva secreted during the collection period was
evaluated. The secretory rate was determined as previously
described [11]. The maximum rates of salivary secretion were
calculated as the weight of saliva divided by the number of
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mouse-body weight (in grammes). For the determination of
chloride saliva samples were diluted 1:20 with deionized water
and the assay was performed using the QuantiChrom™ Chloride
Assay Kit (BioAssay Systems, Hayward, USA) according to the
manufacturer's directions.2.3. Statistics
All results are expressed as means. Error bars are given as the
standard error of the mean (SEM). Statistical analysis was
performed using Graph Pad Prism Software v5.03 (La Jolla,
USA). For the investigation of significant differences between two
groups, Student's paired t test was performed. One way ANOVA
followed by Tukey's multiple comparison test was used to deter-
mine statistical significance between more groups. A probability
value of p b 0.05 was considered as significantly different.3. Results
3.1. Strain dependency of salivary secretion
In the first set of experiments the salivary secretion assay
(SSA) was performed in C57Bl/6, FVB/N, Sv/129 and C3H/He
mice according to standard-protocols [8,10]. The basal saliva
flow rates of both, male and female mice combined (n = 10/
sex, total n = 20) were between 3.5 and 5.4 [μg g−1 min−1]
and did not significantly differ between mouse strains
(Table 1). Acetylcholine-stimulated responses (ACh) reached
the highest salivary rates in C57Bl/6 mice with 42.2 ± 2.8
[μg g−1 min−1], followed by significantly lower rates in FVB/N,
Sv/129 and C3H/He mice with 29.4 ± 1.9 [μg g−1 min−1],
19.2 ± 3.1 [μg g−1 min−1] and 18.9 ± 4.0 [μg g−1 min−1],
respectively (Table 1). Administration of Atropine (ACh/Atro)
significantly inhibited the salivary flow to similar levels in all
mouse strains, but most significantly in the C57Bl/6 mice with
1.1 ± 0.2 [μg g−1 min−1] (Table 1). Finally, substantial differ-
ences in the β-adrenergically stimulated salivary flow rates
between mouse strains were found. The highest salivation was
detected in C3H/He mice and C57Bl/6 mice with an average
secretory rate of 45.9 ± 3.1 [μg g−1 min−1] and 45.1 ± 3.8
[μg g−1 min−1], respectively. The salivary flow rate in FVB/N
and Sv/129 mice with 34.7 ± 3.4 and 26.6 ± 3.5 [μg g−1 min−1]
respectively, was significantly lower (Table 1). Thus, our
experiments indicated a strain-dependency of the saliva secretionTable 1
Average weight [g] and maximum saliva flow rates [μg g−1 min−1] of different mu
Mouse strain Weight Basal
C57Bl/6 22.9 ± 0.4⁎ 3.5 ± 0.4
FVB/N 23.4 ± 0.5 5.2 ± 0.8
Sv/129 22.2 ± 0.5 4.8 ± 0.5
C3H/He 23.5 ± 0.5 5.4 ± 0.9
n = 20 animals/group, data are mean ± SEM.
*/**/*** = Significant versus C57Bl/6 with p b 0.05 /0.01/0.001 (One-way ANOV
#/##/### = Significant versus C3H/He with p b 0.05/ 0.01/ 0.001 (One-way ANOVat basal conditions, as well as after Isoprenaline-stimulation in the
presence of atropine.
3.2. Sex-dependency of salivary secretion
Sex-specific salivary flow rates were investigated in groups
of male and female mice with 10 animals of each sex (Table 2).
Flow rates were related to the body weight of mice. The average
body weights of female mice were similar between strains,
ranging from 19.9 ± 0.3 to 21.4 ± 0.5 [g], but significantly lower
when compared to male mice, ranging from 24.5 ± 0.3 to 25.8 ±
0.4 [g] (Table 2). Female C57Bl/6 and FVB/N mice showed
significantly reduced basal salivary rates compared to their male
counterparts. The salivary rates of male and female C57Bl/6 mice
were 4.6 ± 0.6 [μg g−1 min−1] and 2.4 ± 0.2 [μg g−1 min−1],
respectively (Table 2). Similar data were obtained from FVB/N
mice, in which secretory rates of male mice were 6.6 ± 0.9
[μg g−1 min−1] and also nearly twice that of females (3.8 ± 0.6
[μg g−1 min−1]) (Table 2). No sex-specific differences in the
basal salivary rates among Sv/129 and C3H/He mice were found
(Table 2).
Acetylcholine (ACh) stimulation of saliva flow rates was
similar in both sexes of C57Bl/6 and Sv/129 mice and not
significantly different (Table 2). In contrast, in FVB/N ACh-
stimulated saliva flow was significantly higher in females
(37.6 ± 2.8 [μg g−1 min−1]) compared to males (21.3 ± 1.0
[μg g−1 min−1]), whereas in C3H/He mice it was significantly
higher in males (26.0 ± 3.9 [μg g−1 min−1]) compared to
females (11.9 ± 4.1 [μg g−1 min−1]) (Table 2).
Cholinergic blockade with Atropine (Atro) inhibited ACh-
stimulated salivary flow in male and female mice to a sim-
ilar extent and no significant sex-dependency was found
(Table 2).
However, after isoprenaline stimulation in the presence of
Atropine (Iso/Atro), a sex-specific significant difference in
salivary flow rates was found (Table 2). Female C57Bl/6 mice
had significantly lower salivary rates (38.4 ± 2.0 [μg g−1 min−1])
compared to males: (51.8 ± 5.6 [μg g−1 min−1]). In contrast, in
Sv/129 and C3H/He male mice had significantly lower salivary
rates than their female littermates. Salivary rates for female
and male Sv/129 mice were 32.8 ± 3.4 and 20.4 ± 3.6
[μg g-1 min−1], respectively (Table 2) Salivary rates for female
and male C3H/He mice were 49.2 ± 2.4 [μg g−1 min−1] and
42.6 ± 3.8 [μg g−1 min−1], respectively. FVB/N mice showed
equal β-adrenergic-stimulated salivary secretion in both sexes
(females: 35.9 ± 2.7; males: 33.5 ± 9.1 [μg g−1 min−1]; Table 2).rine backgrounds.
ACh Atro/ACh Iso/Atro
42.2 ± 2.8 1.1 ± 0.2 45.1 ± 3.8#
29.4 ± 1.9⁎⁎⁎ 1.8 ± 0.3 34.7 ± 3.4⁎⁎/##
19.2 ± 3.1⁎⁎⁎ 2.3 ± 0.3⁎⁎ 26.6 ± 3.5⁎⁎⁎/###
18.9 ± 4.0⁎⁎⁎ 1.6 ± 0.4 45.9 ± 3.1
A followed by Tukey´s Multiple Comparison post-hoc analysis).
A followed by Tukey's Multiple Comparison post-hoc analysis).
Table 2
Average weight [g] and maximum saliva flow rates [μg g−1 min−1] from male and female mice.
Mouse strain Sex Weight Basal ACh Atro/ACh Iso/Atro
C57Bl/6 Male 24.8 ± 0.5 4.6 ± 0.6 43.6 ± 3.6 1.0 ± 0.2 51.8 ± 5.6
Female 21.1 ± 0.2*** 2.4 ± 0.2** 40.7 ± 2.1 1.2 ± 0.2 38.4 ± 2.0***
FVB/N Male 25.8 ± 0.4 6.6 ± 0.9 21.3 ± 1.0 2.0 ± 0.3 33.5 ± 9.1
Female 21.0 ± 0.5*** 3.8 ± 0.6* 37.6 ± 2.8*** 1.6 ± 0.3 35.9 ± 2.7
Sv/129 Male 24.5 ± 0.3 4.3 ± 0.4 18.3 ± 3.3 2.0 ± 0.3 20.4 ± 3.6
Female 19.9 ± 0.3*** 5.3 ± 3.6 20.2 ± 2.9 2.6 ± 0.3 32.8 ± 3.4*
C3H/He Male 25.5 ± 0.5 5.4 ± 0.6 26.0 ± 3.9 1.2 ± 0.1 42.6 ± 3.8
Female 21.4 ± 0.5*** 5.4 ± 1.4 11.9 ± 4.1* 2.0 ± 0.6 49.2 ± 2.4*
n = 10 animals/sex, Data are mean ± SEM, */**/*** = significant versus male with p b 0.05/ 0.01/ 0.001 (Student's paired t test).
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dependency as well as sex-specificity of saliva secretion rates in
mice.
3.3. Salivary secretion in CF mice
The salivary secretion assay was intended to characterize
compounds which could have potential for the treatment of
CFTR-linked CF. We therefore investigated salivary rates in
groups of 20 sex-matched (10 animals/sex) CFTR-knockout
mice (CFTRtm1Unc) as well as two strains carrying the F508del
mutation, namely CFTRtm1Eur and CFTRtm1Kth. Secretion rates
were compared in homozygous (CF) and heterozygous (Hz)
mice as in their corresponding wild-type littermates (WT).
CF-mice were growth-retarded and had significantly lower
body weights compared to Hz and WT mice (Table 3).
All CF-mice exhibited very similar basal salivary rates
between 3.3 and 3.7 [μg g−1 min−1] and did not differ
significantly between WT, Hz and CF (Fig. 1A). The
Acetylcholine-stimulated (ACh) saliva flow was also almost
identical between the different CF-mice and the different
genotypes. CFTRtm1Unc and CFTRtm1Kth mice had salivary
flow rates between 50.0 ± 6.2 and 54.8 ± 8.2 [μg g−1 min−1],
whereas CFTRtm1Eur animals showed slightly reduced secretion
rates between 41.8 ± 4.7 and 47.7 ± 5.0 [μg g−1 min−1]
(Fig. 1B). Blockade of ACh-stimulation with atropine (ACh/
Atro) significantly inhibited salivary flow to a similar extent in all
CF-mice and genotypes (Fig. 1C). After stimulation of saliva
flowwith isoprenaline (Iso) in the presence of atropine (Iso/Atro),
substantial differences in the salivary rates between the different
CF-models and different genotypes were found. Wild-type (WT)
CFTRtm1Unc mice exhibited the highest Iso-stimulated secretion
rates with 53.9 ± 4.9 [μg g−1 min−1] which was significantlyTable 3
Average weight [g] of sex-matched CF mouse models.
CF-mouse strain CF
CFTRtm1Unc 16.5 ± 0.4#/^^
CFTRtm1Kth 16.3 ± 0.5⁎/^
CFTRtm1Eur 20.8 ± 0.4°°°/^^^
n = 20 animals/group, data are mean ± SEM.
*/**/*** = Significant versus CF with p b 0.05/0.01/0.001 (One-way ANOVA foll
#/##/### = Significant versus WT with p b 0.05/0.01/0.001 (One-way ANOVA fol
°/°°/°°° = Significant versus CFTRtm1Unc with p b 0.05/0.01/0.001 (One-way ANO
^/^^/^^^ = Significant versus CFTRtm1Kth with p b 0.05/0.01/0.001 (One-way ANOlower in CFTRtm1Kth WT and CFTRtm1Eur WT mice with 42.9 ±
2.1 and 34.6 ± 4.2 [μg g−1 min−1], respectively (Fig. 1D, black
bars). Heterozygous (Hz) salivary responses to β-adrenergic
stimulation were significantly reduced to approximately 50%
of the WT response in all CF-mice. Hz CFTRtm1Unc and Hz
CFTRtm1Kth had the highest, but not significantly different, sali-
vary flow rates with 24.3 ± 3.7 and 21.6 ± 1.6 [μg g−1 min−1],
respectively, whereas Hz CFTRtm1Eur mice showed significantly
lower rates with 14.7 ± 1.2 [μg g−1 min−1] (Fig. 1D, grey bars).
Homozygous CF mice (CF) had the lowest salivary rates. Salivary
secretion rates were equal between CF CFTRtm1Kth and CF
CFTRtm1Eur mice, with 3.4 ± 0.4 and 3.4 ± 0.5 [μg g−1 min−1]
respectively, but significantly lower in CF CFTRtm1Unc mice with
1.8 ± 0.6 [μg g−1 min−1] (Fig. 1D, white bar). In summary, mice
carrying the F508del mutation showed substantially reduced
salivary secretion rates which were further decreased in CF
knock-out mice.
3.4. Salivary chloride content
To render the salivary secretion assay more translational
to the human sweat test, the salivary chloride content after
β-adrenergic stimulated salivation in 20 sex-matched CFTRtm1Eur
mice was determined (10 animals/sex). Significant differences in
salivary chloride content were found among homozygous (CF),
heterozygous (Hz) and wild-type (WT) CFTRtm1Eur mice with
79.3 ± 4.9 [mM], 53.9 ± 7.2 [mM] and 32.3 ± 2.0 [mM],
respectively (Fig. 2). This increase of salivary chloride content
in CF CFTRtm1Eur mice resembles the abnormally high
sweat-chloride in CF-patients. However, the human sweat test is
pilocarpine-, not adrenaline-driven. We therefore additionally
determined the chloride content of pilocarpine-stimulated saliva
in CFTR-knockout mice (CFTRtm1Unc) as well as in F508delHz WT
23.2 ± 0.5⁎⁎⁎/## 24.9 ± 0.5⁎⁎/^^^
21.9 ± 0.5⁎⁎⁎/##/° 27.2 ± 0.6⁎⁎⁎
24.0 ± 0.5⁎⁎⁎/###/°° 25.0 ± 0.6⁎⁎⁎/°/^^^
owed by Tukey's Multiple Comparison post-hoc analysis).
lowed by Tukey's Multiple Comparison post-hoc analysis).
VA followed by Tukey's Multiple Comparison post-hoc analysis).
VA followed by Tukey's Multiple Comparison post-hoc analysis).
A Bbasal ACh
D
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Fig. 1. Average maximum saliva flow rates from homozygous (CF, white bars), heterozygous (Hz, grey bars) and wild-type (WT, black bars) CFTRtm1Unc,
CFTRtm1Kth and CFTRtm1Eur mice. (A) Basal salivary flow rates. (B) Acetylcholine-stimulated salivary flow rates. (C) Acetylcholine-stimulated salivary flow rates in
the presence of atropine. (D) Isoprenaline-stimulated salivary flow rates in the presence of atropine. Data are expressed asmean ± SEM. n = 20/group. Significant differences
were determined by Tukey's multiple comparison test (*/**/*** = significant versus WT with p b 0.05/0.01/0.001; #/##/### = significant versus heterozygous with
p b 0.05/0.01/0.001; °/°°/°°° = significant versus CFTRtm1Unc with p b 0.05/0.01/0.001; ^/^^/^^^ = significant versus CFTRtm1Kth with p b 0.05/0.01/0.001).
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concentrations were found to be 48.6 ± 3.1 [mM] in WT
CFTRtm1Unc, 50.3 ± 4.2 [mM] in WT CFTRtm1Kth and
39.9 ± 3.1 [mM] in WT CFTRtm1Eur mice (Fig. 3A–C,
black bars). The saliva from heterozygous mice contained a
significantly higher chloride content than wild-type saliva.
The chloride concentrations were 75.4 ± 3.2 [mM] for Hz
CFTRtm1Unc, 71.3 ± 3.4 [mM] for Hz CFTRtm1Kth, and
66.2 ± 3.8 [mM] for Hz CFTRtm1Eur (Fig. 3A–C, grey
bars). However, the highest chloride concentrations were found
in the saliva of homozygous CF mice, amounting to 97.3 ± 3.2
[mM] for CF CFTRtm1Unc, 96.9 ± 3.8 [mM] for CF CFTRtm1Kth
and 123.2 ± 3.7 [mM] for CF CFTRtm1Eur (Fig. 3A–C, white
bars). In summary, CF-mice exhibit significantly elevated salivary
chloride contents, comparable to sweat chloride concentration in
CF patients.Fig. 2. Salivary chloride content in Isoprenaline-stimulated saliva from wild-
type (WT; black bars), heterozygous (Hz; grey bars) and homozygous (CF;
white bars) CFTRtm1Eur mice. Data are expressed as mean ± SEM. n = 5 pools
with a total of 30 mice. Significant differences were determined by Tukey's
multiple comparison test (*/**/*** = significant with p b 0.05/0.01/0.001).4. Discussion
Despite substantial efforts in research and development during
decades, there is still no approved therapy for the pharmacologicalrestoration of F508del trafficking and function available. In recent
years, a variety of compounds were discovered, which were able to
restore F508del function in vitro [4], but despite promising in vitro
effects, most drugs failed in clinical studies [15–17]. This raised
635K. Droebner, P. Sandner / Journal of Cystic Fibrosis 12 (2013) 630–637concerns about the predictivity of the preclinical in vitro and in
vivo models. Since the salivary secretion assay (SSA) in F508del
mice is easy to perform and suitable to test potential new
compounds in vivo, we revisited this assay. Though introduced
very early, unfortunately very little information is available
regarding secretion rates, especially in the context of different
mouse strains, different mutations, and sex-specificity. We
therefore investigated secretory responses in different mouse
backgrounds used for generating CF mouse models [14],
(Table 1 and Fig. 1) and also explored possible gender differences
in these mouse strains (Table 2).
Although there are no particular reports describing different
salivary secretory responses in distinct mouse strains, several
studies delineate behavioural and physiologic differences in
inbred mice relative to spontaneous mutations and geneticCFTRtm1Kth 
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Fig. 3. Salivary chloride content in Pilocarpine-stimulated saliva from wild-type
(WT; black bar), heterozygous (Hz; grey bars) and homozygous (CF; white
bars) CFTRtm1Unc, CFTRtm1Kth and CFTRtm1Eur mice. Data are expressed as
mean ± SEM. n = 8/group. Significant differences were determined by Tukey's
multiple comparison test (*/**/*** = significant with p b 0.05/0.01/0.001).strain differences [18,19]. We found significant strain-specific
quantitative and qualitative variations in mouse saliva secre-
tion. The strains C57Bl/6 and FVB/N showed strong secretory
responses to cholinergic activation, whereas the strongest
adrenergic salivary responses were found among C57Bl/6
and C3H/He mice followed by FVB/N mice (Table 1). This
background-dependency of the salivary response was also
maintained in the CF mice (Fig. 1). We found significantly
higher β-adrenergic secretion responses amongWT CFTRtm1Unc
and CFTRtm1Kth mice, which were in the C57Bl/6 background, as
compared with CFTRtm1Eur mice (FVB/N background; Fig. 1).
From this data one might conclude that C57Bl/6 mice are the
most suitable for the SSA. However, besides the background
of the mouse models, sex-specific salivary secretion behaviour
might also influence the results. Accordingly, we found
pronounced sex-specific differences in salivary secretion after
cholinergic stimulation in FVB/N and C3H/He mice (Table 2).
Moreover, adrenergic stimulated secretory responses differed
significantly between all strains except FVB/N mice (Table 2).
This sexually dimorphism in our experiments most likely
depends on the mode of stimulation used to elicit saliva secretion.
We hypothesize that this might be related to a sex- and perhaps
also strain-specific expression pattern of sympathetic and para-
sympathetic receptors in the male and female salivary gland. It is
already known, that especially in salivary glands of male and
female mice variations in mRNA expression, but also morpho-
logical, chemical and physiological differences exist [20,21].
Therefore, the murine sex-specific salivary secretion behaviour
is driven by non-CF factors and does not fully reflect the
human situation in sweat secretion [22,23]. However, due to the
absence of sexual dimorphism in the adrenergic salivary response
in FVB/N mice, the CFTRtm1Eur mice might be very suitable for
therapeutic studies of F508del CFTR correction and potentiation
and in this case both sexes of mice can be used.
The impaired physiological response to β-adrenergic stimula-
tion of salivary secretion in CF-mice is the basis for testing
experimental therapeutics.Wewere able to confirm the previously
described, decreased β-adrenergic salivary response in CFTR
deficient mice (Fig. 1), [8,11]. However, these results provide only
limited information for approaches targeting the F508del
mutation. Therefore, we also investigated the isoprenaline-driven
saliva flow rates in two strains carrying the F508del mutation,
namely CFTRtm1Kth, which were in the C57Bl/6 background and
CFTRtm1Eur mice in the FVB/N background (Fig. 1). The
secretory rates of CF F508del CFTRtm1Kth and CFTRtm1Eur were
nearly three times higher when compared to those of the
knock-out CFTRtm1Unc mice (Fig. 1). This might be explained at
least in part by the fact that homozygous F508del mice express
a low amount of functional CFTR in their apical epithelia,
while CFTR knockouts do not express CFTR protein [24,14].
Nevertheless, depending on the genetic background F508del
animals showed also significantly decreased saliva flow rates after
β-adrenergic stimulation. This substantially reduced β-adrenergic
saliva flow rates in homozygous F508del mice render the SSA
also suitable for the testing of CFTR correctors. Despite these
advantages of the SSA, so far only a few studies have used this
method for in vivo testing of new compounds [9,11]. This might
636 K. Droebner, P. Sandner / Journal of Cystic Fibrosis 12 (2013) 630–637be due to the limitations in translating murine salivary fluid
secretion data into the clinical situation in CF-patients. Although,
the use of β-adrenergic sweat secretion was proposed as
diagnostic tool, only few experimental clinical data are available
[25–27]. In contrast to sweat secretion, sweat chloride content is
an accepted diagnostic readout in CF patients and also allows
detecting treatment effects [28,29].We therefore focused on saliva
chloride content in CF mice (Figs. 2, 3). Firstly, we investigated
the chloride concentration of β-adrenergic stimulated saliva from
CF mice (Fig. 2). We found substantial differences in the chloride
content of homozygous CF, heterozygous and wild-type mice,
which mimic findings in CF patients. However, the very low
amount of saliva secreted by homozygous CF mice stimulated
by Iso/Atro hampers the accurate determination of its chloride
content. Moreover, blockade of the cholinergic system and
adrenergic-stimulated saliva production differs from the standard
human sweat test protocol for chloride measurements which uses
only pilocarpine as a stimulus [29]. Therefore, pilocarpine
stimulated saliva production and the salivary chloride content
from CF-mice was investigated. Depending on the CF mouse
model the chloride concentrations in saliva of homozygous
CF-mice in comparison to wild-type littermates were significantly
elevated, ranging from 1.8 in CFTRtm1Kth mice to 3.3-fold in
CFTRtm1Eur mice (Fig. 3). These differences, especially between
WT and CF of CFTRtm1Eur mice are very similar to those found
between healthy individuals and CF patients that show an
approximately 5-fold elevation of sweat chloride concentration
[30]. This marked increase in Cl− content is indicative for an
important but often neglected Cl−-absorptive function of CFTR in
the duct compartment of the salivary gland, in addition to its
secretory role in the acinar cells, and mimicking its function in the
absorptive duct of the human sweat gland. To our knowledge, no
prior study has investigated the changes of salivary chloride after
treatment with potential CF-drugs. In addition, the degree to
which a given drug reduces the murine salivary chloride content
might easily be correlated with a reduction of sweat chloride in
CF-patients making this modified salivary secretion assay a better
surrogate of the human sweat test.
Taken together our results demonstrate that the quantifica-
tion of salivary secretion in both sexes of CFTRtm1Kth and
CFTRtm1Eur CF mouse models, extended by the determination
of salivary chloride content, may render this test as an effective
and clinically translatable screening tool with high predictive
value. This could facilitate and accelerate the in vivo profiling
of effective CFTR-modulators in the future.
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